Hyperlipidemia / High Cholesterol Medication Refills Treatment
Covered by Aetna in California

Atorvastatin 40–80mg daily (high-intensity statin, Tier 1 generic — first-line for high-risk patients with established ASCVD, diabetes, or 10-year ASCVD risk ≥10% per ACC/AHA 2026 dyslipidemia guidelines; LDL-C target <70 mg/dL for high-risk, <55 mg/dL for very-high-risk secondary prevention); rosuvastatin 20–40mg daily (alternative high-intensity statin — Tier 1 generic); ezetimibe 10mg daily added when LDL target not met on maximally tolerated statin

Moderate-intensity statins for lower-risk primary prevention: atorvastatin 10–20mg or rosuvastatin 10mg (LDL-C target <100 mg/dL for borderline/intermediate risk); pravastatin 40mg (Tier 1, preferred for statin-intolerant patients and drug-interaction-prone patients — fewer CYP3A4 interactions); fluvastatin XL 80mg (lowest myopathy risk — for patients with prior statin myopathy on other agents); bempedoic acid 180mg (Nexletol — oral, non-statin, reduces LDL ~18–22%, useful for statin-intolerant patients; works via upstream ACL inhibition, does not affect muscle tissue)

Yes — all generic statins and ezetimibe are Tier 1 on Aetna CA commercial plans (~$4–$30/month). PCSK9 inhibitors (Repatha, Praluent) require PA; if approved, specialty Tier 3–4 — manufacturer patient assistance programs significantly reduce out-of-pocket cost. Bempedoic acid is Tier 3 and may require PA. ACC/AHA 2026 guidelines support statin use for primary and secondary prevention — Aetna CA covers screening lipid panels under preventive benefit for eligible patients.

ACC/AHA 2026 Dyslipidemia Guidelines (released March 2026) introduce the PREVENT risk calculator (replacing Pooled Cohort Equations) and return to specific LDL-C targets: <70 mg/dL for high-risk primary prevention, <55 mg/dL for secondary prevention with ASCVD events. Lipoprotein(a) should now be measured once per lifetime (Class I recommendation) — elevated Lp(a) ≥50 mg/dL warrants more aggressive LDL lowering. ApoB measurement now has a defined pathway for risk assessment when LDL is at goal. Telehealth refills appropriate for stable hyperlipidemia with documented prior lab values; new patients requiring baseline lipid panel or cardiovascular risk stratification may need in-person evaluation first.

TDMD can document the clinical criteria needed for a PCSK9 inhibitor PA, but these medications require Aetna's specialty prior authorization review. The criteria per Aetna Clinical Policy are: documented ASCVD (prior MI, stroke, or coronary revascularization), current LDL ≥70 mg/dL despite maximally tolerated statin therapy (plus ezetimibe if tolerated). 'Maximally tolerated' means you have tried and either failed to reach LDL target or developed intolerance on the highest dose of at least one high-intensity statin. Your visit documentation from Dr. Bhavsar will include your LDL trend, prior statin history, and ASCVD event history to support the PA application. Manufacturer patient assistance programs for Repatha and Praluent can reduce out-of-pocket cost to $0–$50/month for commercially insured patients.

Statin-associated muscle symptoms (SAMS) affect approximately 5–10% of patients on high-intensity statins. Dr. Bhavsar can evaluate whether your symptoms represent statin myopathy versus coincidental musculoskeletal pain using a validated assessment approach. Management options include: dose reduction to atorvastatin 40mg or switching to rosuvastatin 20mg (often better tolerated); switching to pravastatin or fluvastatin (lowest myopathy risk); reducing to every-other-day dosing; adding CoQ10 (supportive evidence limited but widely used); or, for truly statin-intolerant patients, transitioning to bempedoic acid 180mg plus ezetimibe (oral non-statin combination that achieves 30–40% LDL reduction). CK elevation >10× upper limit of normal requires drug discontinuation — if you have dark urine, stop the statin and go to urgent care.

For established patients on a stable statin dose, a recent lab result is helpful but not always required for a refill if you had testing within the past 12 months. Aetna CA does not require a specific lab to be on file to process a pharmacy claim. Dr. Bhavsar will review any available recent labs and may order a lipid panel through your preferred lab (Quest or LabCorp — widely accessible across California) if more than 12 months have passed, to confirm your LDL is at goal and guide any dose adjustment. Annual monitoring is standard for statin patients.

Yes. Aetna commercial plans cover telehealth visits for Hyperlipidemia / High Cholesterol Medication Refills in California. TeleDirectMD (Dr. Parth Bhavsar, MD, NPI: 1104323203) is an in-network telehealth provider with Aetna in California. Your standard Aetna telehealth copay applies — typically $10–$40 for most commercial plans. If clinically appropriate, your prescription is sent to your California pharmacy immediately after your visit.

Most Aetna commercial plans in California have telehealth copays of $10–$40. Often $0–$20 for employer plans. Your exact cost depends on your specific plan and whether your deductible has been met. Log into your Aetna member portal or call the member services number on your card to verify your telehealth copay before your high cholesterol (hyperlipidemia) refills visit. Self-pay is always available for a flat $49 if you prefer to skip insurance.

If your specific Aetna plan is not in-network with TeleDirectMD in California, or if your deductible has not yet been met, you can book as a self-pay patient for a flat $49 fee — same physician, same quality of care, no insurance needed. You may also be eligible to submit an out-of-network claim to Aetna for partial reimbursement depending on your plan's out-of-network benefit.

TeleDirectMD typically offers same-day and next-day video visits. Book at teledirectmd.com/book-online and select a time that works for you. Most patients are seen within a few hours of booking during business hours. Your high cholesterol (hyperlipidemia) refills symptoms are evaluated by Dr. Bhavsar, MD — not a nurse practitioner or PA — ensuring you receive a board-certified clinical assessment.

Yes. TeleDirectMD is operated by Dr. Parth Bhavsar, MD (NPI: 1104323203), a board-certified Family Medicine physician. TeleDirectMD is LegitScript certified, HIPAA compliant, and is contracted as an in-network telehealth provider with Aetna in California. Claims are billed using standard CPT codes (99213/99214) and submitted electronically to Aetna.

Yes. Telehealth visits with a licensed physician are qualified medical expenses eligible for FSA (Flexible Spending Account) and HSA (Health Savings Account) payment. If your Aetna plan applies your deductible first, your FSA or HSA card can be used to pay your portion. The $49 self-pay option is also FSA/HSA eligible.